Pharma's Almanac TV
PA TV
Your Name
Your Email
Manage Account
Sign Out
Sign In
Register
Follow the Journey
Companies On The Road
Arcadis DPS Group
C2 Pharma
CAI
EcoLab
Environmental Systems Corporation
Federal Equipment Company
Globyz Biopharma Services
Grifols
Integrity
Nu-Tek BioSciences
PHARMALEX
Waters Corporation
Follow the Journey
Companies On The Road
ABS
aCGT Vector
Alconox Inc.
Andelyn Biosciences
Arranta Bio
Avid Bioservices
BDD
BIOVECTRA
DPS Group
Dynamk Capital
Environmental Systems Corporation
Federal Equipment Company
Genesis AEC
Globyz Biopharma Services
Grifols Partnership
IDT Biologika
Inceptor Bio
IPS-Integrated Project Services
Kineticos Life Sciences
MilliporeSigma
Montana BioScience Alliance
Olon
Rentschler Biopharma
SanaClis
Scorpion Biological Services
Secant Group
Tapemark
VITRONIC
Follow the Journey
Companies On The Road
AES Clean Technology
Altis Biosystems
Arranta Bio
Avara Pharmaceutical Services
Avid Bioservices
BioVectra
Centaur BPS
Dynamk Capital
ECRI
Evolve Biologics
Federal Equipment Company
Globyz
Inceptor Bio
IPS-Integrated Project Services
Olon
Pii
Polpharma Biologics
PPD
RoosterBio
SanaClis
Sanofi AIS
SGD Pharma
SPI Pharma
TriRx Pharmaceutical Services
Yourway
Dashboard
Topics
Products
ADC
API - Small Molecule
Biologics
Biopharmaceuticals
Biosimilars
Cell and Gene Therapy
DNA
Drug Product
Drug Substance
Equipment
Generics
Immunotherapy
Injectables
Monoclonal Antibody
Novel Therapeutics
Oral Solid Dosage
Orphan Drugs
Parenterals
Stem Cells
Vaccine
Services
Big Data
Bioprocessing
Clinical Trials
Continuous Manufacturing
Diagnostics
Drug Delivery
Drug Development
Drug Discovery
Facility
Formulation
Innovation
Oncology
Patient Adherence
Patient Centric
Preclinical
Process Development
Quality
Regulatory
Research
Serialization
Segment
Biomanufacturing
Biotechnology
CDMO
Consulting
CRO
Engineering
Equipment
Excipients
Healthcare
Intermediates
Logistics
Manufacturing
Packaging
Supply Chain
Business
Agreement
Appointment
Business
Capacity Expansion
Collaboration
Growth
Investment
Licensing
M&A
Market Expansion
Market Intelligence
Market Prediction
New Facility
Strategic Partnership
Magazine
Archive
Reports
Nice Insight Reports
2022 Sterile
2023 Cell & Gene Therapy
2023 mAb and Recombinant Protein
2024 API
2024 OSD
2024 ADC
2024 mRNA
2024 Mammalian Cell Culture
2024 Microbial Cell Culture
2024 Plasmids
2024 Gene Therapy
2024 Cell Therapy
2024 Sterile
Community
Company A to Z
Follow the Journey
Companies On The Road
Follow The Artist
Follow the Journey
Companies On The Road
More+
Staffing
Media Kit
FDA Statement (2)
45 Articles Available
2
2
Can't find what you're looking for? Try our
advanced search
.
FDA
FDA Warns about Claims of Aging and Memory Loss Prevention with Infusions of Young Donor Plasma
PAO-M02-19-NI-021
FDA Statement
Statement from FDA Commissioner Scott Gottlieb, M.D., On New Policy to Improve Access for Drugs that Face Inadequate Generic Competition
PR-M02-19-NI-039
FDA Statement
Statement from FDA Commissioner Scott Gottlieb, M.D. on New Programs to Promote the Adoption of Innovations in Drug Manufacturing
PR-M02-19-NI-034
FDA Statement
Statement from FDA Commissioner Scott Gottlieb, M.D., on Ongoing Efforts to Secure the U.S. Supply Chain and Confront the Opioid Epidemic
PR-M02-19-NI-032
FDA
FDA Statement Announcing Efforts to Improve the Quality of the Information Used to Assess the Effectiveness of REMS Programs
PR-M01-19-NI-078
Digital Health
Statement from FDA Commissioner on the Agency's New Actions under the Pre-Cert Pilot Program to Promote a More Efficient Framework for the Review of Safe and Effective Digital Health Innovations
PR-M01-19-NI-025
FDA
FDA Report on Declining Sales/Distribution of Antimicrobial Drugs for Food Animals, a Reflection of Improved Antimicrobial Stewardship
PR-M12-18-NI-068
FDA
Statement from FDA Commissioner on New Steps to Promote Innovations in Medical Devices that Help Advance Patient Safety
PR-M12-18-NI-067
Medical Device
Statement from Jeff Shuren, Director of the CDRH, on Updated Safety Communication About Rates of Duodenoscope Contamination from Preliminary Postmarket Data
PR-M12-18-NI-062
FDA Statement
Statement from FDA Commissioner Scott Gottlieb, M.D., on New Actions Advancing the Agency's Biosimilars Policy Framework
PR-M12-18-NI-049
FDA Statement
Statement from FDA Commissioner Scott Gottlieb, M.D., on the FDA's New Effort for Developing and Class Labeling of In Vitro Companion Diagnostics for Classes of Oncology Therapeutic Products
PR-M12-18-NI-034
FDA Statement
Statement from FDA Commissioner Scott Gottlieb, M.D., on FDA's New Strategic Framework to Advance Use of Real-World Evidence to Support Development of Drugs and Biologics
PR-M12-18-NI-031
FDA Statement
Statement from FDA Commissioner Scott Gottlieb, M.D., on How Modern Predicates Can Promote Innovation and Advance Safety and Effectiveness of Medical Devices that Use 510(k) Pathway
PR-M12-18-NI-007
FDA Statement
Statement from FDA Commissioner Scott Gottlieb, M.D. and Jeff Shuren, M.D., Director of the CDRH, on FDA's Medical Device Safety Action Plan to enhance post-market safety
PR-M11-18-NI-094
FDA
FDA Warns Marketers of Products Labeled as Dietary Supplements that Contain Tianeptine for Making Unproven Claims to Treat Serious Conditions
PR-M11-18-NI-090
FDA
Statement by FDA Commissioner Scott Gottlieb, M.D., on the FDA's Efforts to Hold Industry Accountable for Fulfilling Critical Post-marketing Studies
PR-M11-18-NI-077
PR-M11-18-NI-076
Statement by FDA Commissioner Scott Gottlieb, M.D., on Efforts to Reduce Animal Testing Through a Study Aimed at Eliminating the Use of Dogs in Certain Trials
PR-M11-18-NI-075
FDA
Statement from FDA Commissioner Scott Gottlieb, M.D., on Proposed New Steps to Protect Youth by Preventing Access to Flavored Tobacco Products
PR-M11-18-NI-058
FDA Statement
Statement from FDA Commissioner Scott Gottlieb, M.D., on Agency's Approval of Dsuvia and the FDA's Future Consideration of New Opioids
PR-M11-18-NI-016
FDA Statement
Statement from FDA Commissioner Scott Gottlieb, M.D., on the FDA's new consideration of labeling for sesame allergies
PR-M10-18-NI-109
FDA Statement
Statement from FDA Commissioner Scott Gottlieb, M.D., on FDA's Comprehensive Framework to Reduce Tobacco-related Disease and Death
PR-M10-18-NI-078
«
2
2